The 1296-041 DELFIA Plate Dispense allows the automatic and precise addition of liquids to all wells or to selected strips of the DELFIA microtitration plate. To minimize background and to avoid foam
Precision 2000 is an affordable, innovative solution for automated 96-/384-well microplate liquid handling. With its ability to perform virtually any routine liquid transfer, Precision 2000 replaces
Multidrop DW is a high-speed automated dispenser for Deep Well plates, 1.1 ml test tubes and 96-well plates. Designed for accuracy and precision, the Multidrop DW dispenses up to eight different reag
...nts and increased throughput, particularly for scr...ated dispenser designed for high-throughput screen...ll plates.This new-generation dispenser offers out...- to 384- well plates and dispense up to 8 differe...
Medicine Products:(Date:12/3/2008)... 4 Cell Therapeutics, In...resentations or posters of interest,related to Ze... the 50th,Annual Meeting of the American Society ...ancisco. , In addition, James Bianco, M.D.,...anel hosted by Biotechnology Industry Organization...
(Date:12/3/2008)...PHIA) A novel angled gantry approach to coronary ...reast by more than 50%, according to Thomas Jeffer...., associate professor of Radiology at Jefferson M...hiladelphia, presented the research at the 94th Sc...ogical Society of North America. , "Radiation do...
(Date:12/3/2008)...land, MD, Professor and Chairman of Neurology at L...dicine, is the principal investigator of two studi...athy a common degenerative nerve disorder that to...aluation and management. The studies, published in...e issue of Neurology , resulted in recommendation...
(Date:12/3/2008)..., Dec. 3 In recognition...ASH) places on mentorship, ASH is proud to honor G...th ASH Mentor Awards, which highlight the importan...al development of hematologists early in their car...om the discipline of laboratory science and the ot...
Breaking Medicine News(10 mins):Health News:Zevalin Data to be Presented at ASH 2008 2Health News:Zevalin Data to be Presented at ASH 2008 3Health News:Zevalin Data to be Presented at ASH 2008 4Health News:Zevalin Data to be Presented at ASH 2008 5Health News:LSUHSC's England leads development of new testing guidelines for common nerve disorder 2Health News:Inspirational Hematologists Honored With Mentor Awards From the American Society of Hematology 2(Date:12/3/2008)... Vical Incorporated,(Na...ng letter of intent with EIP,Eczacibasi Ilac Paza...mpany,s,Allovectin-7(R) immunotherapeutic product...Northern Cyprus. EIP has agreed to obtain the nece...to pay Vical upfront and milestone payments,plus ...
(Date:12/2/2008)...PRNewswire-USNewswire/ -- Breast-specific gamma im...cers not found on mammograms or by,clinical exam,...l meeting of,the Radiological Society of North Am... difficult to detect breast cancer-invasive,lobul...D., professor of,radiology and director of the Br...
(Date:12/2/2008).... 2 IBT Laboratories, a leading c...tory specializing in immunology and allergy assays...luate the response of patients whose immune syste...iency disorder, chemotherapy drugs, or because the...ejection of a transplant. The company launched the...
(Date:12/2/2008).... 2 Horizon Therapeutics, Inc., a,...nnounced that two pivotal,Phase 3 trials evaluati...-501,met all primary endpoints. HZT-501, a novel...aining ibuprofen and famotidine, demonstrated a,s...e of non-steroidal,anti-inflammatory drug (NSAID)...
Breaking Medicine Technology:Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey 2Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey 3Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey 4Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey 5New Breast Imaging Technology Targets Hard-to-Detect Cancers 2New Breast Imaging Technology Targets Hard-to-Detect Cancers 3IBT Laboratories Expands its Menu of Tests for Immune Deficiency 2Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 2Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 4Mannatech to Open Centralized Management Office in Switzerland 9395 1Mannatech to Open Centralized Management Office in Switzerland 9395 2EVICEL 28TM 29 Fibrin Sealant 28Human 29 Approved for General Hemostasis in Surgery 2549 1EVICEL 28TM 29 Fibrin Sealant 28Human 29 Approved for General Hemostasis in Surgery 2549 2Fighting pollution the poplar way 3A Trees to clean up Indiana site 1848 1Fighting pollution the poplar way 3A Trees to clean up Indiana site 1848 2Fighting pollution the poplar way 3A Trees to clean up Indiana site 1848 3Extreme obesity affects chances of kidney transplantation 9391 1Extreme obesity affects chances of kidney transplantation 9391 2... WOODLANDS, Texas--(BUSINESS WIRE)--Apr 3, 2007 - ... involved in the,development and commercialization...ine data in an open-label Phase I/II dose,escalati...ccine,Tovaxin(TM), for multiple sclerosis. In thi...ial, Tovaxin therapy was shown to be,safe and effe...
...ADENA, Calif.--(BUSINESS WIRE)--Apr 3, 2007 - Arro...d the publication by its,majority-owned subsidiary...ating the anti-proliferative effect of the siRNA s...ts lead anti-cancer,compound, CALAA-01., The paper...ide,Reductase Subunit RRM2 Reduce Cell Proliferati...
Other Medicine Technology:Opexa Therapeutics Reports Positive Top-line Data in Phase I/II,Dose Escalation Trial with Tovaxin for Multiple Sclerosis 2Opexa Therapeutics Reports Positive Top-line Data in Phase I/II,Dose Escalation Trial with Tovaxin for Multiple Sclerosis 3Opexa Therapeutics Reports Positive Top-line Data in Phase I/II,Dose Escalation Trial with Tovaxin for Multiple Sclerosis 4Arrowhead Subsidiary Calando Pharmaceuticals Publishes Study,Showing Anti-Cancer Effect with Lead RNAi Candidate 2Arrowhead Subsidiary Calando Pharmaceuticals Publishes Study,Showing Anti-Cancer Effect with Lead RNAi Candidate 3